Post hoc analysis of a phase 3 trial in 1879 adults with type 2 diabetes: at 40 weeks, 34% on semaglutide met three or more standard targets (HbA1c, BP, LDL, weight) vs 42%, 53% and 57% on tirzepatide 5, 10 and 15 mg.
Secondary analysisn = 1,879
Neves et al. Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial